Exposure-response analyses of tigecycline tolerability in healthy subjects

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 2, 2009, Pages 123-129

  Passarell, Julie ^a   Ludwig, Elizabeth ^a   Liolios, Kathryn ^a   Meagher, Alison K ^a   Grasela, Thaddeus H ^a   Babinchak, Timothy ^b   Ellis Grosse, Evelyn J ^c  

^a Albany Medical College   (United States)

^b PFIZER INC   (United States)

^c e2g Biopharmaceutical Consulting   (United States)

Author keywords

Exposure response; Nausea; Tigecycline; Tolerability; Vomiting

Indexed keywords

PLACEBO; TIGECYCLINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOGISTIC REGRESSION ANALYSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; NAUSEA; TIME FACTORS; VOMITING; YOUNG ADULT;

EID: 69949102076     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.06.019     Document Type: Article

References (22)

1. Ambrose P.G., Meagher A.K., Passarell J.A., Van Wart S.A., Cirincione B.B., Rubino C.M., Korth-Bradley J.M., Babinchak T., and Ellis-Grosse E. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 63 (2009) 38-42
2. Ambrose P.G., Meagher A.K., Passarell J.A., Van Wart S.A., Cirincione B.B., Bhavnani S.M., and Ellis-Grosse E. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis. 63 (2009) 155-159
3. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., and Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl 5 (2005) S354-S367
4. Bhattaram V.A., Bonapace C., Chilukuri D.M., Duan J.Z., Garnett C., Gobburu J.V., Jang S.H., Kenna L., Lesko L.J., Madabushi R., Men Y., Powell J.R., Qiu W., Ramchandani R.P., Tornoe C.W., Wang Y., and Zheng J.J. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 81 (2007) 213-221
5. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5 (2005) S341-S353
6. Food and Drug Administration. Exposure-response relationships-study designs, data analysis, and regulatory applications (2003), FDA Guidance for Industry
7. 14C]tigecycline in human volunteers following intravenous infusion. [abstract 2540]. AAPS PharmSci 6 S1 (2004). http://www.aapspharmsci.org/ Available from:
8. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm 63 (2006) 1235-1243
9. Meagher A.K., Liolios K., Passarell J., Cirincione B.B., Van Wart S.A., Fiedler-Kelly J., Babinchak T., and Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic (PK/PD) model for the safety of tigecycline (t) in patients with complicated intra-abdominal infections (cIAI). Presented at (ECCMID) 16th European Congress of Clinical Microbiology and Infectious Diseases Nice, France. (poster) (2006)
10. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., Ellis-Grosse E.J., and Ambrose P.G. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 51 (2007) 1939-1945
11. Muralidharan G., Micalizzi M., Speth J., Raible D., and Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49 (2005) 220-229
12. Muralidharan G., Fruncillo R.J., Micalizzi M., Raible D.G., and Troy S.M. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 49 (2005) 1656-1659
13. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 25 (2005) 185-192
14. Passarell J.A., Meagher A.K., Cirincione B.B., Van Wart S.A., Babinchak T., and Ellis-Grosse E.J. Exposure-response analysis of the efficacy of tigecycline in patients with complicated intra-abdominal infections. Presented at (ICAAC) Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., (platform) (2005)
15. Passarell J.A., Meagher A.K., Liolios K., Cirincione B.B., Van Wart S.A., Babinchak T., Ellis-Grosse E.J., and Ambrose P.G. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 52 (2008) 204-210
16. Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J., and Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 26 (2004) 704-714
17. SAS Institute Inc. SAS/STAT® user's guide, version 8 (1999), SAS Institute Inc., Cary, NC 3884
18. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 43 (2006) 518-524
19. Story M.J., McCloud P.I., and Boehm G. Doxycycline tolerance study. Incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs Vibramycin'). Eur J Clin Pharmacol 40 (1991) 419-421
20. Troy S.M., Muralidharan G., Micalizzi M., Mojavarian P., Salacinski L., and Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 43 5 (2003) 55
21. Van Wart S.A., Cirincione B.B., Ludwig E.A., Meagher A.K., Korth-Bradley J.M., and Owen J.S. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 47 (2007) 727-737
22. Wyeth Research. Tygacil (tigecycline) for injection (2007) Philadelphia, PA [product information]